Strive, Inc. (ASST) Stock Price & Analysis
Strive, Inc. (ASST) fell 6.57% to USD 14.21 as of June 10, 2026 at 03:41 UTC, according to Nexqual real-time market data.
ASST last closed at USD 15.21; the session ranged USD 13.65–15.24 on volume of 4,074,218 shares. Market capitalization is $1.13B, with a 52-week range of USD 7.02–252 (NGM). Source: Nexqual, June 10, 2026 at 03:41 UTC.
Key Statistics (as of June 10, 2026 at 03:41 UTC)
| Price | USD 14.21 |
|---|---|
| Change | ▼ 6.57% (down) |
| Previous Close | USD 15.21 |
| Open | USD 14.66 |
| Day Range | USD 13.65 – 15.24 |
| 52-Week Range | USD 7.02 – 252 |
| Volume | 4,074,218 shares |
| Market Cap | $1.13B |
| Exchange | NGM |
Technical Analysis (ASST)
Nexqual's technical model rates ASST "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:41 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.75 (neutral) |
| vs SMA50 | Below (USD 14.86) |
| MACD | -0.15 (negative) |
Analyst Ratings (ASST)
Wall Street analysts rate ASST "Strong Buy" based on 5 analysts, with a mean price target of USD 29.6 (range USD 20–36), per Nexqual as of June 10, 2026 at 03:41 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 29.6 |
| High Target | USD 36 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (ASST)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.25 |
| Revenue Estimate | $3.05M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -5.19 vs est -0.12 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:41 UTC.
Financials & Fundamentals (ASST)
| Total Revenue | $7.03M |
|---|---|
| Revenue Growth (YoY) | +88.20% |
| Gross Margin | +0.00% |
| Operating Margin | -11363.73% |
| Profit Margin | +0.00% |
| ROE | -125.42% |
| Debt / Equity | 1.22 |
| Current Ratio | 11.44 |
| Total Cash | $145.60M |
| Total Debt | $13.12M |
| Free Cash Flow | $-320.68M |
Source: Nexqual, June 10, 2026 at 03:41 UTC.
Financial Health Score (ASST)
Nexqual rates Strive, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:41 UTC.
| Growth | Strong — Revenue +88% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $146M cash vs $13M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$321M, burning cash |
| Efficiency | Critical — ROE -125%, ROA -62.6% |
Ownership (ASST)
| Insider Ownership | +1.54% |
|---|---|
| Institutional Ownership | +49.34% |
| Shares Outstanding | 69.41M |
| Float | 56.75M |
| Short % of Float | +21.35% |
Source: Nexqual, June 10, 2026 at 03:41 UTC.
Leadership (ASST)
Strive, Inc. is led by Matthew Ryan Cole C.F.A. (age 39), Chairman & CEO, per Nexqual as of June 10, 2026 at 03:41 UTC.
| Chairman & CEO | Matthew Ryan Cole C.F.A. (age 39) |
|---|---|
| CFO & Director | Benjamin Bartley Pham (age 30) |
| Chief Legal Officer & Director | Brian Logan Beirne (age 43) |
| Chief Strategy Officer & Board Observer | Avik Roy (age 51) |
| Chief Marketing Officer & Director | Arshia Sarkhani (age 27) |
Major Backers & Investors (ASST)
Notable institutional backers of Strive, Inc. include FMR, LLC, Fidelity, Capital International Investors, according to Nexqual as of June 10, 2026 at 03:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 11.3% |
| Fidelity | 5.1% |
| Capital International Investors | 4.17% |
| SmallCap World Fund Inc | 4.17% |
| Morgan Stanley | 2.78% |
| UBS Group AG | 1.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.25% |
| Vanguard Group | 7.32% |
| Geode Capital | 1.93% |
| State Street | 1.86% |
Source: Nexqual, June 10, 2026 at 03:41 UTC.
From Strive, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Healthcare Technology Solutions Products and Services Our subsidiary, Semler Scientific, currently markets a patented and FDA-cleared, vascular testing product, QuantaFlo.
- Semler Scientific previously reported that it is experiencing and expects to continue to experience decreased usage of its QuantaFlo device due various factors, including the 2024 Medicare Advantage and Part D Final Rate Announcement issued by the Centers for Medicare and Medicaid Services ("CMS").
- Executive Branch, Congress and a number of U.S. federal and state agencies, including the Financial Crimes Enforcement Network, the Commodity Futures Trading Commission ("CFTC"), the U.S.
- A blood flow waveform is instantaneously constructed by our proprietary software algorithm.
Partnerships
- Semler Scientific has been cooperating with civil investigative demands from DOJ (as defined below) since 2017 related to claims for reimbursement related to Semler Scientific's QuantaFlo device and entered into a settlement agreement with DOJ related thereto in September 2025.
- Relative to a traditional depreciating fiat-denominated benchmark, implementing a bitcoin hurdle rate establishes a higher level of accountability and strategic investment discipline, since our decisions are measured against an asset we believe will appreciate over time.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GPUS | Hyperscale Data, Inc. | USD 0.17 | ▲ 10.73% |
| CIFR | Cipher Digital Inc. | USD 23.04 | ▲ 2.61% |
| SBET | SharpLink, Inc. | USD 5.32 | ▲ 2.5% |
| DVLT | Datavault AI Inc. | USD 0.4 | ▼ 6.86% |
| BURU | Nuburu, Inc. | USD 0.15 | ▼ 7.81% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:41 UTC. This page is informational and not investment advice.